HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response.

Abstract
Intrauterine and neonatal manifestations of congenital long QT syndrome are associated with a high cardiac risk, particularly when atrioventricular block and excessive QT prolongation (> 600 ms(1/2)) are present. In a female newborn with these features, treatment with propranolol and mexiletine led to complete reduction of arrhythmia that was maintained 1.5 years later. High throughput genetic analysis found a sodium channel gene (LQT3) mutation. Disappearance of the 2:1 atrioventricular block and QTc shortening (from 740 ms(1/2) to 480 ms(1/2)), however, was achieved when mexiletine was added to propranolol. This effect was considered to be possibly genotype related. Early onset forms of long QT syndrome may benefit from advanced genotyping.
AuthorsE Schulze-Bahr, H Fenge, D Etzrodt, W Haverkamp, G Mönnig, H Wedekind, G Breithardt, H-G Kehl
JournalHeart (British Cardiac Society) (Heart) Vol. 90 Issue 1 Pg. 13-6 (Jan 2004) ISSN: 1468-201X [Electronic] England
PMID14676229 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Electrocardiography
  • Female
  • Genotype
  • Humans
  • Infant, Newborn
  • Long QT Syndrome (congenital, diagnosis, therapy)
  • Mutation (genetics)
  • Pedigree
  • Phenotype
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: